EAACI Congress 2024
BackENT 1
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
Ear, Nose and Throat Manifestations in Eosinophilic Granulomatosis with Polyangiitis (EGPA) patients at time of diagnosis: our experience
12:00
Early Responders within One Month of Dupilumab Treatment for Chronic Rhinosinusitis with Nasal Polyps
12:00
Investigating the Role of Skin Prick and Specific IgE Tests in Nasal Provocation Test Outcomes for Allergic Rhinitis Diagnosis
12:00
Involvement of activation of mast cells via IgE signaling and epithelial cell-derived cytokines in the pathogenesis of pollen-food allergy syndrome in a novel murine model
12:00
Minimal Invasive Endotyping in Nasal Inflammatory Disease
12:00
Ocular symptoms in Local Allergic Rhinitis
12:00
Performance of 5 item and 22 item sino-nasal outcome tests in response to dupilumab in chronic rhinosinusitis with nasal polyps
12:00
Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years
12:00
Serious secondary effect of rhinitis self-treatment: Reversible Cerebral Vasoconstriction Syndrome (RCVS)
12:00
The survey of perennial allergic rhinitis caused by house dust mites among the elementary school students in Fukui, Japan
12:00
Use of Corticosteroids and History of Surgery Among Patients with CRSwNP Initiating Dupilumab in the Global AROMA registry
